isoxazoles has been researched along with cep-32496 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abraham, S; Apuy, JL; Armstrong, RC; Ator, MA; Bhagwat, S; Campbell, BT; Chao, Q; Cramer, MD; Dorsey, BD; Ezawa, M; Faraoni, R; Gardner, MF; Ghose, AK; Gibney, M; Gitnick, D; Gunawardane, RN; Herbertz, T; Holladay, MW; Hua, H; Insko, DE; James, J; Jones-Bolin, S; Lai, AG; Nepomuceno, RR; Rowbottom, MW; Ruggeri, B; Setti, E; Sprankle, KG; Struss, B; Tran, L; Valenta, I; Williams, M | 1 |
1 other study(ies) available for isoxazoles and cep-32496
| Article | Year |
|---|---|
Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (B
Topics: Administration, Oral; Animals; Binding, Competitive; Cell Line, Tumor; Cell Proliferation; Dogs; Drug Screening Assays, Antitumor; Female; Humans; Isoxazoles; Macaca fascicularis; Male; Mice; Mice, Nude; Microsomes, Liver; Models, Molecular; Mutation; Neoplasm Transplantation; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Quinazolines; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous | 2012 |